Dr. Michael Crump

Bispecific antibodies have emerged as potent new therapy for resistant aggressive lymphomas. Integration of this new class of immunotherapy agents into the DLBCL algorithm represents new opportunities and new challenges, including timing relative to other treatments in the relapsed setting, and the management of cytokine release syndrome and prevention and management of infections. Opportunities for bringing these agents into the front-line, high-risk setting will be described.

Speaker: Dr. Michael Crump
Professor of Medicine at the University of Toronto and attending physician in the Division of Medical Oncology and Hematology at the Princess Margaret Hospital, University Health Network

Learning Objectives:
1) Indications for bispecifics in DLBCL
2) practical considerations/tips for use of bispecifics
3) management of infections with bispecifics
4) choosing between different bispecific agents/evidence supporting one or the other in DLBCL

REGISTER TODAY! Registration is open to all.

Accreditation: This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists (CAP-AC). You may claim a maximum of 1.0 hours. Certificates of Attendance will be sent to all CHS members who participate.

This webinar is supported by a grant from Hoffman La Roche and the CHS Scientific Planning Committee has planned it to achieve scientific integrity, objectivity and balance.

Conflict of Interest:

• Clinical Trial funding: Roche; Epizyme
• Advisory board honoraria: Kite/Gilead

Target Audience: Hematologists and trainees